Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Mesothelioma & Rare Thoracic

Ravi Salgia

拉维·萨尔贾

MD, PhD

🏢City of Hope Comprehensive Cancer Center(希望之城综合癌症中心)🌐USA

Professor and Chair, Department of Medical Oncology and Therapeutics Research肿瘤内科与治疗研究系教授兼主任

60
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Ravi Salgia at City of Hope is a preeminent expert in thymic malignancies and MET signaling in thoracic cancers. He has developed MET-targeted therapies for lung cancer and thymic tumors, led international cooperative trials for rare thoracic malignancies, and built City of Hope's world-class thoracic oncology program.

Share:

🧪Research Fields 研究领域

Thymic Malignancies胸腺恶性肿瘤
MET SignalingMET信号通路
Rare Thoracic Cancers罕见胸部肿瘤

🎓Key Contributions 主要贡献

MET Oncology

Defined the oncogenic role of MET receptor tyrosine kinase in lung cancer and thymic malignancies, enabling development of crizotinib and subsequent MET inhibitors.

Thymic Malignancy Research

Led pivotal trials for thymoma and thymic carcinoma including pembrolizumab studies, establishing immunotherapy as a viable option for relapsed thymic tumors.

Translational Programs

Built multidisciplinary rare thoracic malignancy programs at City of Hope, integrating genomics, proteomics, and clinical trial infrastructure for thymic, mesothelioma, and carcinoid tumors.

Representative Works 代表性著作

[1]

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Lancet Oncology (2018)

Demonstrated pembrolizumab activity in thymic carcinoma, establishing immunotherapy as a second-line treatment option for this rare malignancy.

[2]

Functional and mutational analysis of MET in non-small cell lung cancer

Journal of Thoracic Oncology (2009)

Comprehensive molecular characterization of MET alterations, guiding patient selection for MET-targeted therapies in thoracic cancer.

[3]

Multi-institutional phase II study of pembrolizumab in thymic epithelial tumors

Journal of Clinical Oncology (2020)

Largest prospective immunotherapy dataset in thymic tumors, informing current treatment guidelines and future combination strategies.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Merit Award
🏆IASLC Heine Hansen Award for Thoracic Oncology
🏆City of Hope Eugene and Ruth Roberts Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 拉维·萨尔贾 的研究动态

Follow Ravi Salgia's research updates

留下邮箱,当我们发布与 Ravi Salgia(City of Hope Comprehensive Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment